Bromperidol maintenance in schizophrenia.
Twenty-three patients who completed a four-week, double-blind, clinical trial of bromperidol versus haloperidol were treated with bromperidol for eight additional weeks in a continuation study. Over 87 percent of patients maintained their improved status or showed further improvement. Extrapyramidal signs were frequent, but required discontinuation of treatment in only two patients.
D004311:Double-Blind Method; D006220:Haloperidol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D006220:Haloperidol; C006820:bromperidol